Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.

Wex, Jaro;Sidhu, Manpreet;Odeyemi, Isaac;Abou-Setta, Ahmed M;Tombal, Bertrand;et.al.
(2013) ClinicoEconomics and Outcome Research — Vol. 5, p. 257-269 (2013)

Files

Wex-2013-LeuprolideacetateI.pdf
  • Open Access
  • Adobe PDF
  • 417.31 KB
Download

Details

Authors
  • Wex, Jaro
    Author
  • Sidhu, Manpreet
    Author
  • Odeyemi, Isaac
    Author
  • Abou-Setta, Ahmed M
    Author
  • Tombal, Bertrandorcid-logoUCLouvain
    Author
Show more
Abstract
Eligard® formulations offer comparable efficacy and safety, but different dosing schedules require different number of visits. The 6 M formulation offers the greatest cost savings and should be considered the treatment of choice in eligible patients in Europe.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Wex, J., Sidhu, M., Odeyemi, I., Abou-Setta, A. M., Retsa, P., & Tombal, B. (2013). Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation. ClinicoEconomics and Outcome Research, 5, 257-269. https://doi.org/10.2147/CEOR.S44855 (Original work published 2013)